Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORA-4 phase 3 study of lisaftoclax plus azacitidine in newly diagnosed higher-risk myelodysplastic syndrome
CTR20243841Phase 3Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisaftoclax, azacitidine in myelodysplastic syndrome (MDS), sponsored by Suzhou Yasheng Pharmaceutical. Started Feb 2025; status: active.
02
Drugs
lisaftoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20243841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243841.